Risk of hepatitis B virus reactivation in patients treated with ibrutinib
Sarah P. Hammond(Dana-Farber Cancer Institute), Francisco M. Marty(Brigham and Women's Hospital), Nicolas C. Issa(Dana-Farber Cancer Institute), Alisha Pandit(Brigham and Women's Hospital), Matthew S. Davids(Dana-Farber Cancer Institute), Kaiwen Chen(Brigham and Women's Hospital)
Cited by 60
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752
Small molecules, big impact: 20 years of targeted therapy in oncology
|The Lancet|2020|606